Antibodies for the treatment and diagnosis of affective and anxiety disorders
AssigneePhenoQuest AG
InventorsIngeborg Sillaber, Marcelo Paez-Pereda
Life of this patent
Estimating the term…
Abstract
A novel monoclonal antibody and like antigen-binding molecules against transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFE2) are provided with unique immunological and biological properties useful in the therapy of affective disorders such as depression and bipolar disorders as well as anxiety disorders. In addition, pharmaceutical compositions and kits comprising such antibody and derivatives thereof are described.
Claims20
An antibody or antigen-binding fragment thereof specifically binding transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFF2), which antibody is capable of
- (a) increasing Activin induced Smad-regulated signaling pathway activity in TMEFF2 over-expressing CHO cells;
- (b) displaying anxiolytic properties in the novelty-induced hypophagia (NIH) paradigm test;
- and/or
- (c) displaying antidepressive properties in the forced swim test (FST).
Dependencies are inferred from the claim text.